Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by bilosellhion Apr 30, 2005 11:41pm

214 Views

Post# 8980196

RE: Stockhouse Censorship

robtooclueless, you have no reason or justification to knock anyone, except perhaps trying to knock some sense into your own obviously lacking brain. time for you to re-read this again, idiot. https://www.stockhouse.ca/bullboards/viewmessage.asp?no=8770702&all=0&t=1&archived=Archive&TableID=1

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading